Eyepoint Pharmaceuticals Inc (EYPT) — Cash Flow Reinvestment Rate
Eyepoint Pharmaceuticals Inc (EYPT) has a Cash Flow Reinvestment Rate of 0.25x as of June 2023, reinvesting $14.26 Million (capex $396.00K plus investments $13.86 Million) from operating cash flow of $57.02 Million. Check EYPT cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Eyepoint Pharmaceuticals Inc Cash Flow Reinvestment Rate (2010–2023)
Historical reinvestment intensity for Eyepoint Pharmaceuticals Inc across 3 annual periods. Explore EYPT cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Eyepoint Pharmaceuticals Inc (2010–2023)
Year-by-year capital reinvestment analysis for Eyepoint Pharmaceuticals Inc. For live market cap and broader valuation context, see Eyepoint Pharmaceuticals Inc market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 3.63x | $6.80 Million | $1.88 Million | $3.48 Million | ▲ +727.8% |
| 2015 | 0.44x | $4.51 Million | $10.30 Million | $161.00K | ▲ +28804.5% |
| 2010 | 0.00x | $15.00K | $9.90 Million | $15.00K | — |